0000899243-22-021008.txt : 20220603
0000899243-22-021008.hdr.sgml : 20220603
20220603170658
ACCESSION NUMBER: 0000899243-22-021008
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220601
FILED AS OF DATE: 20220603
DATE AS OF CHANGE: 20220603
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith-Whitley Kim
CENTRAL INDEX KEY: 0001860297
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 22995617
MAIL ADDRESS:
STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC.
STREET 2: 181 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-01
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001860297
Smith-Whitley Kim
C/O GLOBAL BLOOD THERAPEUTICS, INC.
181 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
See Remarks
Common Stock
2022-06-01
4
M
0
6040
A
6040
D
Common Stock
2022-06-01
4
F
0
1660
24.02
D
4380
D
Restricted Stock Units
2022-06-01
4
M
0
6040
0.00
D
Common Stock
6040
18120
D
Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,040 shares of Common Stock underlying the Reporting Person's RSUs.
The shares of Common Stock underlying the RSUs vested with respect to 25% of the underlying shares on June 1, 2022 and will vest in six equal semi-annual installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Officer Title: EVP, Head of Research & Development
/s/ Miguel Carrillo, Attorney-in-Fact
2022-06-03